Key result
Neoadjuvant VDC/IE chemotherapy achieves complete pathological response in primary renal Ewing sarcoma.
Why the study?
Primary renal Ewing sarcoma is a rare, aggressive small round cell tumor for which optimal management remains uncertain.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Neoadjuvant VDC/IE chemotherapy can achieve substantial tumor shrinkage and pathological complete response in primary renal Ewing sarcoma with IVC involvement, facilitating radical nephrectomy, though systemic relapse remains a risk.
Primary renal Ewing sarcoma is a rare, aggressive small round cell tumor for which optimal management remains uncertain. A 26-year-old man presented with intermittent gross hematuria. Contrast-enhanced computed tomography (CT) showed a 12.8 × 11.3 × 12.3 cm right renal mass with inferior vena cava (IVC) involvement. An initial core biopsy was nondiagnostic. Repeat biopsy showed a small cell malignancy with CD99 immunoreactivity and EWSR1 rearrangement by fluorescence in situ hybridization (FISH), supporting the final pathological diagnosis of Ewing sarcoma. The patient received five cycles of alternating vincristine, doxorubicin, and cyclophosphamide with ifosfamide and etoposide (VDC/IE). CT demonstrated tumor shrinkage to approximately 5.7 × 4.0 cm, although right renal vein and IVC filling defects remained in the preoperative report. Right radical nephrectomy with removal of enlarged hilar lymph nodes was performed on July 20, 2020. Postoperative pathological findings included treatment-related fibrosis and no residual malignant tumor, but detailed tumor-bed sampling data were unavailable. The last available CT, dated November 10, 2022, showed no mass in the operative bed, bilateral pulmonary nodules suspicious for metastases, and IVC thrombosis. This case illustrates substantial tumor regression permitting surgery, while emphasizing the need to distinguish local treatment response from durable systemic disease control.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted a case report in Primary renal Ewing sarcoma with inferior vena cava tumor thrombus (n=1). Neoadjuvant alternating vincristine, doxorubicin, and cyclophosphamide with ifosfamide and etoposide (VDC/IE) followed by right radical nephrectomy was evaluated on Pathological and radiological tumor response. Five cycles of neoadjuvant VDC/IE chemotherapy shrank the primary renal Ewing sarcoma from 12.8 x 11.3 x 12.3 cm to 5.7 x 4.0 cm, with no residual malignant tumor on pathology.
Synapse has enriched 10 related papers. Consider them for comparative context: